Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 13.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of IRLAB Therapeutics AB was 13.90% per year. The lowest was -96.80% per year. And the median was -8.90% per year.
IRLAB Therapeutics AB (OSTO:IRLAB A) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
IRLAB Therapeutics AB 3-Year EBITDA Growth Rate Related Terms
OSTO:IRLAB A vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, IRLAB Therapeutics AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IRLAB Therapeutics AB 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where IRLAB Therapeutics AB's 3-Year EBITDA Growth Rate falls into.
IRLAB Therapeutics AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 13.90% mean?
IRLAB Therapeutics AB (OSTO:IRLAB A) has a 3-Year EBITDA Growth Rate of 13.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IRLAB Therapeutics AB and its competitors. According to the industry distribution chart, IRLAB Therapeutics AB ranks #583 out of 1131 companies in the Biotechnology industry, placing it in the top 51.5%.
Is IRLAB Therapeutics AB's 3-Year EBITDA Growth Rate too high?
IRLAB Therapeutics AB's current 3-Year EBITDA Growth Rate is 13.90%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. IRLAB Therapeutics AB's value of 13.90% is 6.7% below this industry median. Based on the distribution chart, IRLAB Therapeutics AB ranks #583 out of 1131 companies in the Biotechnology industry, which is below the industry midpoint. Overall, IRLAB Therapeutics AB has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IRLAB Therapeutics AB's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, IRLAB Therapeutics AB ranks #583 out of 1131 companies for 3-Year EBITDA Growth Rate. This places IRLAB Therapeutics AB in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. IRLAB Therapeutics AB's value of 13.90% is 6.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,131 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IRLAB Therapeutics AB's current 3-Year EBITDA Growth Rate of 13.90% is 6.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for IRLAB Therapeutics AB and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IRLAB Therapeutics AB's current 3-Year EBITDA Growth Rate is 13.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IRLAB Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, IRLAB Therapeutics AB (OSTO:IRLAB A) is currently considered Possible Value Trap. The stock's GF Value™ is kr11.64, compared to a current price of kr1.57 — trading 86.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 13.90% and 6.7% below the Biotechnology industry median of 14.90. IRLAB Therapeutics AB's overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For IRLAB Therapeutics AB (OSTO:IRLAB A), the current 3-Year EBITDA Growth Rate is 13.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?
Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued.
The current stock price of kr1.57 is trading 86.5% below its estimated GF Value™ of kr11.64.
GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.
Key valuation signals for OSTO:IRLAB A:
3-Year EBITDA Growth Rate: 13.90%
GF Value™: kr11.64 vs. price of kr1.57 (86.5% below fair value)
Industry Position: 6.7% below the Biotechnology median (#583 of 1131)
No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
35GF Score
Get the complete analysis for OSTO:IRLAB A
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IRLAB A has been successfully added to your 
